Quavonlimab
As of the edition of 20 October 2026, Quavonlimab is an antibody: of no established status; acts on CTLA4.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Status not established
- Kind
- Antibody
- Registered trials
- 11, 0 stopped early
- Disease areas
- Cancer; Pregnancy and women's health; Urinary and reproductive; Skin and connective tissue; Digestive system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CTLA4 | Cytotoxic T-lymphocyte protein 4 | P16410 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 9 | 6 | 3 | 0 |
| Phase 3 | 2 | 0 | 2 | 0 |
| All trials | 11 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Merck & Co. | Lead sponsor of trials | 2017 to now |